Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus CLISTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus CLISTIN.
BENYLIN vs CLISTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Clistin (histamine-1 receptor antagonist) competitively blocks histamine at H1 receptor sites, inhibiting vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
4 mg orally every 4-6 hours as needed; maximum 24 mg/day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In patients with renal impairment, half-life may be prolonged, requiring dose adjustment.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Primarily renal excretion (approximately 85-90% as unchanged drug and metabolites). Biliary/fecal elimination accounts for the remainder (10-15%).
Category C
Category C
Antihistamine
Antihistamine